Contemporary directions in the therapy of sensory hearing loss.

IF 1 Q3 OTORHINOLARYNGOLOGY
Polish Journal of Otolaryngology Pub Date : 2024-07-25
Anna Rzepakowska, Aleksandra Borowy, Eryk Siedlecki, Marta Wolszczak, Katarzyna Radomska
{"title":"Contemporary directions in the therapy of sensory hearing loss.","authors":"Anna Rzepakowska, Aleksandra Borowy, Eryk Siedlecki, Marta Wolszczak, Katarzyna Radomska","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>&lt;b&gt;Introduction:&lt;/b&gt; More than 5% of the world's population experience hearing impairment. The most common form is presbycusis (age-related hearing loss; ARHL). It affects almost one in three people over the age of 65. The hair cells of the cochlea play an important role in the process of sound registration. Genetic mutations, aging and environmental factors can cause damage that contributes to the hearing loss.&lt;b&gt;Methods and results:&lt;/b&gt; The currently explored research directions include drug treatments, gene therapies, and stem cell therapies. To date, no significant differences in the therapeutic effect depending on the route of corticosteroid administration have been demonstrated in patients with moderate to severe hearing loss. New dexamethasone-containing hydrogel formulations, as well as lipid formulations, thermosensitive polymers, and nanoparticles, have been developed to achieve high drug concentrations in the inner ear structures. Otoprotective effects of antioxidants or substances that modify the toxic effects of e.g. cisplatin, are also being studied. Attempts at auditory cells' regeneration seem promising in hearing loss research. Substances that regulate the central mechanisms of the Notch and Wnt pathways are being explored to this end. The genetic determinants of presbycusis suggest that interference at the level of specific genes may be a promising option for the treatment of this condition. With the CRISPR/Cas9 technology, the functions of inner ear genes can be effectively studied by disrupting normal gene alleles. The CRISPR/Cas9 complexes developed to target specific genes are delivered using cationic lipids, proteins, and viral vectors. They are then transported through the round window membrane by diffusion, without the need to surgically disrupt the inner ear. The potential of using antisense oligonucleotides to treat hereditary deafness caused by hair cell degeneration has also been established. Another research direction is related to stem cells being used for the development of in vitro 3D models of the human inner ear. Studies are also pursued to identify the mechanisms underlying the formation of cochlear organoids from pluripotent cells as well as determine the critical time points and events for cochlear sensory epithelial development and targeted hair cell differentiation.&lt;b&gt;Conclusions:&lt;/b&gt; In summary, significant progress has been made over the past decade in the search for novel therapies for sensory hearing loss. This line of research remains an ambitious and important area for further exploration.</p>","PeriodicalId":42608,"journal":{"name":"Polish Journal of Otolaryngology","volume":"78 4","pages":"29-38"},"PeriodicalIF":1.0000,"publicationDate":"2024-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Polish Journal of Otolaryngology","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"OTORHINOLARYNGOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

<b>Introduction:</b> More than 5% of the world's population experience hearing impairment. The most common form is presbycusis (age-related hearing loss; ARHL). It affects almost one in three people over the age of 65. The hair cells of the cochlea play an important role in the process of sound registration. Genetic mutations, aging and environmental factors can cause damage that contributes to the hearing loss.<b>Methods and results:</b> The currently explored research directions include drug treatments, gene therapies, and stem cell therapies. To date, no significant differences in the therapeutic effect depending on the route of corticosteroid administration have been demonstrated in patients with moderate to severe hearing loss. New dexamethasone-containing hydrogel formulations, as well as lipid formulations, thermosensitive polymers, and nanoparticles, have been developed to achieve high drug concentrations in the inner ear structures. Otoprotective effects of antioxidants or substances that modify the toxic effects of e.g. cisplatin, are also being studied. Attempts at auditory cells' regeneration seem promising in hearing loss research. Substances that regulate the central mechanisms of the Notch and Wnt pathways are being explored to this end. The genetic determinants of presbycusis suggest that interference at the level of specific genes may be a promising option for the treatment of this condition. With the CRISPR/Cas9 technology, the functions of inner ear genes can be effectively studied by disrupting normal gene alleles. The CRISPR/Cas9 complexes developed to target specific genes are delivered using cationic lipids, proteins, and viral vectors. They are then transported through the round window membrane by diffusion, without the need to surgically disrupt the inner ear. The potential of using antisense oligonucleotides to treat hereditary deafness caused by hair cell degeneration has also been established. Another research direction is related to stem cells being used for the development of in vitro 3D models of the human inner ear. Studies are also pursued to identify the mechanisms underlying the formation of cochlear organoids from pluripotent cells as well as determine the critical time points and events for cochlear sensory epithelial development and targeted hair cell differentiation.<b>Conclusions:</b> In summary, significant progress has been made over the past decade in the search for novel therapies for sensory hearing loss. This line of research remains an ambitious and important area for further exploration.

感官听力损失治疗的当代方向。
<b>简介:</b> 世界上有超过 5% 的人口存在听力障碍。最常见的形式是老花性听力损失(年龄相关性听力损失;ARHL)。几乎每三个 65 岁以上的人中就有一人受到影响。耳蜗的毛细胞在声音记录过程中发挥着重要作用。基因突变、衰老和环境因素都会造成听力损失。<b>方法和结果:</b> 目前探索的研究方向包括药物治疗、基因治疗和干细胞治疗。迄今为止,在中重度听力损失患者中,皮质类固醇给药途径不同,治疗效果也无明显差异。新开发的含地塞米松的水凝胶制剂以及脂质制剂、热敏聚合物和纳米颗粒可使药物在内耳结构中达到高浓度。此外,还在研究抗氧化剂或改变顺铂等药物毒性作用的物质对耳的保护作用。听觉细胞再生的尝试在听力损失研究中似乎很有希望。为此,正在探索调节 Notch 和 Wnt 途径中心机制的物质。老花眼的遗传决定因素表明,在特定基因水平上进行干扰可能是治疗这种疾病的一个有前途的选择。利用 CRISPR/Cas9 技术,可以通过破坏正常基因等位基因来有效研究内耳基因的功能。针对特定基因开发的 CRISPR/Cas9 复合物使用阳离子脂质、蛋白质和病毒载体进行传递。然后,它们通过扩散作用穿过圆窗膜,无需通过手术破坏内耳。利用反义寡核苷酸治疗由毛细胞变性引起的遗传性耳聋的潜力也已得到证实。另一个研究方向是利用干细胞开发人类内耳的体外三维模型。此外,还在研究确定多能细胞形成耳蜗器官组织的机制,以及确定耳蜗感觉上皮发育和定向毛细胞分化的关键时间点和事件。这一研究方向仍然是有待进一步探索的雄心勃勃的重要领域。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Polish Journal of Otolaryngology
Polish Journal of Otolaryngology OTORHINOLARYNGOLOGY-
CiteScore
1.30
自引率
16.70%
发文量
15
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信